Treatment
Specialists Agree on Treatment Options for Controversial Early Stage Breast Cancer
Published in Breast Cancer Weekly, March 4th, 2000
A "who's who" of breast cancer experts from medical institutions around the world have agreed upon a series of treatment options for Ductal Carcinoma In Situ (DCIS), a controversial malignancy found in the breast, as an important new step toward improving patient treatment for this type of early breast cancer. DCIS currently represents 25 to 30% of all breast cancers diagnosed.
In a paper to be published concurrently by three medical journals - Cancer, Human Pathology, and The...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Breast Cancer Weekly
Source: Breast Cancer Weekly (2000-03-04)
More Articles from Breast Cancer Weekly
- Chemotherapy
Encouraging Results Reported for New Breast Cancer Therapy - Clinical Trials
Elderly Population Significantly Underrepresented in Cancer Studies - Diagnostics
Ultrasonography Complements Mammography in Preoperative Evaluation - Drug Development
Are Smaller Antibodies Better? - Drug Interactions
Docetaxel May Interfere with Epirubicin Plasma Level - Genetic Risk
Tumor Phenotype Associated With BRCA1 Mutations - More from this issue of Breast Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
